GLP-1 Agonists | 396

Brief

GLP-1 weight loss drugs are changing the global pharmaceutical market. Products like Ozempic, Wegovy, and Mounjaro are now household names, and competition between drug makers is becoming more intense. As new companies enter this fast-growing market, the question is: who will come out on top?

Overview

In this episode of Down to Business English, Skip Montreux and Dez Morgan get Down to Business with GLP-1 agonists — the drugs behind today’s weight-loss boom. They explain who the main players are, including Novo Nordisk and Eli Lilly, and compare their leading products. The discussion also looks at a major recent development: Pfizer’s acquisition of biopharma startup Metsera, and why this deal could significantly change the market.

Insights

Skip and Dez’s conversation gives listeners a clear and practical introduction to competition and strategy in the pharmaceutical industry — while helping you improve your Business English. In this episode, you will learn:

What GLP-1 drugs are and what they are used for.
The main differences between Ozempic, Wegovy, Mounjaro, and Zepbound.
Why Eli Lilly is gaining market share, especially in North America.
How Pfizer’s acquisition could affect future weight-loss treatments.

In summary

D2B 396 explores how strong demand, new research, and major acquisitions are reshaping the weight-loss drug market. As treatments become more effective and easier to use, competition is likely to increase even further.

Do you like what you hear?

Become a D2B Member today for access to our interactive audio scripts, bonus Down to Vocabulary, and Member-only D2B episodes.

For full access to the Interactive Audio Player, become a D2B Member today.

GLP-1 Agonists | 396

Brief

Overview

Insights

In summary

Do you like what you hear?

Download Audio

Download Audio Script

Be sure to follow to D2B on your favorite podcast client!!